CEO COMMENTS

Kristina Torfgård comments Q1 report 2025

“The first quarter of 2025 has been one of our most dynamic to date, marked by significant regulatory progress, promising clinical results, and the deepening of strategically important partnerships, all collectively strengthening our position. Following an in-depth analysis of the topline data for pirepemat presented during the quarter, we can confidently affirm that all of our development programs continue to make evident progress and bring us closer to our goal – to provide new, effective treatments for people living with Parkinson’s disease.

Key Milestones During the Quarter:

• Promising results from the Phase I study with IRL757 enable the next step in clinical development – a study in patients with Parkinson’s and apathy. Our strategic collaboration with MSRD/Otsuka and the Michael J. Fox Foundation plays an important role in advancing the development of IRL757.
• The regulatory progress for mesdopetam lays a strong foundation for the upcoming Phase III program and deepened discussions with potential partners.
• Study data on pirepemat show a statistically significant and clinically meaningful reduction in fall rate, linked to the plasma concentrations of the drug.

Together, these advances demonstrate that we are well on our way to realizing our vision and creating value for patients, partners and shareholders.”

Q4’23

Year-end report >

Presentation >

Webcast >

Q1’24

Interim report >

Presentation >

Webcast >

Q2’24

Interim report >

Presentation >

Webcast >

Q3’24

Interim report >

Presentation >

Webcast >

FINANCIAL CALENDAR

NEXT

August 27 2025

Interim Report January – June 2025